Table 3.
Description of asthma and COPD treatments
| First line | ||
|---|---|---|
| Asthma | COPD | |
| n = 373 | n = 524 | |
| Asthma + COPD treatments, n (%) | ||
| SABA (Y/N) | 211 (56.6) | 292 (55.7) |
| LABA (Y/N) | 18 (4.8) | 32 (6.1) |
| ICS (Y/N) | 31 (8.3) | 33 (6.3) |
| ICS dose low | 0 | 2 (0.4) |
| ICS dose medium | 26 (7.0) | 27 (5.2) |
| ICS dose high | 7 (1.9) | 8 (1.5) |
| Leukotriene modifiers (Y/N) | 53 (14.2) | 31 (5.9) |
| Theophylline (Y/N) | 3 (0.8) | 6 (1.1) |
| Tiotropium (Y/N) | 26 (7.0) | 69 (13.2) |
| OCS use (Y/N) | 263 (70.5) | 367 (70.0) |
| Systemic corticosteroids (Y/N) | 286 (76.7) | 381 (72.7) |
| Controller medication | 131 (35.1) | 171 (32.6) |
| 1 type of controller mediation (Y/N) | 91 (24.4) | 119 (22.7) |
| 2 types of controller medications (Y/N) | 32 (8.6) | 44 (8.4) |
| ≥ 3 types of controller medications (Y/N) | 8 (2.1) | 8 (1.5) |
| ICS only | 3 (0.8) | 1 (0.2) |
| ICS + SABA | 10 (2.7) | 14 (2.7) |
| ICS + LABA | 98 (26.3) | 126 (24.0) |
| Triple or more therapy | 13 (3.5) | 16 (3.1) |
| COPD specific | ||
| LAMA (Y/N) | 61 (16.4) | 129 (24.6) |
| LAMA + LABA (Y/N) | 5 (1.3) | 9 (1.7) |
| Long-term oxygen use (Y/N) | 1 (0.3) | 8 (1.5) |
| Systematic antibiotics (Y/N) | 217 (58.2) | 303 (57.8) |
ICS inhaled corticosteroid, LABA long-acting beta agonist, LAMA long-acting muscarinic antagonist, OCS oral corticosteroid, SABA short-acting beta agonist, Y/N yes or no response